SciSparc’s Subsidiary NeuroThera Labs Granted Japanese Patent for its Proprietary, Innovative Therapeutic Combination

In Tel Aviv, Israel on August 12, 2026, SciSparc Ltd. (Nasdaq: SPRC) revealed that NeuroThera Labs Inc. (TSXV: NTLX), a clinical-stage pharmaceutical firm specializing in innovative therapies for central nervous system ailments, has obtained a patent from the Japanese Patent Office for their pharmacological blend titled “Compositions and Methods for Potentiating Derivatives of 4-Aminophenols.” This patent marks a significant milestone for NeuroThera, highlighting its commitment to advancing treatments in this field.